Are there any upcoming catalyst events (e.g., product launches, partnership announcements, conference presentations) that could drive further price movement?

Catalyst Outlook

TOMI’s Q2 filing flags two near‑term catalysts that could reignite momentum. In the earnings release the company highlighted “upcoming launch of the next‑generation Binary Ionization Technology (BIT‑2) platform” slated for an industry showcase in early‑September (the International MedTech Expo, Sep 12‑14). The same commentary notes a pending “strategic partnership with a leading U.S. health‑system network” that the company expects to announce “in the coming weeks” and will be reflected in the Q3 earnings call (scheduled for early October). Both events are explicitly referenced as drivers of the “growth initiatives” and therefore represent concrete upcoming news items that could trigger a price swing.

Trading Implications

Fundamentally, the company posted modest Q2 revenue growth but a net‑loss that keeps the sentiment score low (30). Technicals show the stock hovering just above its 20‑day EMA (~$6.45) but below the 50‑day EMA (~$6.80) and near a short‑term resistance band around $6.70. A breakout above $6.80 on volume could signal the market is pricing in the upcoming product/partner announcements; a break below $6.40 would likely invalidate the upside thesis.

Actionable Play

- Bullish scenario: Enter a small‑to‑moderate long position on a pull‑back to $6.40‑$6.45 with a stop just below $6.30. Target the $6.80‑$7.00 range, which aligns with the prior high and the 50‑day EMA, anticipating a catalyst‑driven rally.

- Bearish safeguard: If price breaches $6.30 on high volume, consider scaling out or flipping to a short‑term defensive put (e.g., a 30‑day put spread with strike $5.90) to protect against a potential negative surprise (e.g., delayed partner deal).

Monitoring the Sep 12‑14 Expo and the Q3 earnings call will be key—any material update from those events is likely to trigger a decisive move in TOMZ’s price.